Authors’ Reply to Gandjour: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”

A. T. Newall, M. Jit, R. Hutubessy

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)1247
Number of pages1
JournalPharmacoEconomics
Volume32
Issue number12
DOIs
StatePublished - Nov 26 2014

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this